Lantern Pharma

Lantern Pharma's LP-184 receives second FDA Fast Track Designation for TNBC, following earlier designation for Glioblastoma. LP-184, developed with AI platform RADR®, shows tumor regression in TNBC models and is in Phase 1A trial for solid tumors.

Lantern Pharma shares rose 6% to $3.34 after FDA granted fast-track designation for LP-184 in triple negative breast cancer. This is the second fast-track designation for LP-184 in 2024, following glioblastoma in October. LP-184 is currently in a Phase 1A trial for safety and tolerability in solid tumors.

FDA grants Fast Track Designation to LP-184 for TNBC, recognizing its potential to address unmet needs in aggressive cancers. LP-184 demonstrated significant preclinical efficacy in TNBC models, including those resistant to PARP inhibitors, and shows promising synergy with checkpoint inhibitors. The drug is currently in a Phase 1A clinical trial for multiple solid tumors, including TNBC.

Lantern Pharma Inc. announced the first patient dosed in Japan for its Phase 2 HARMONIC™ trial, evaluating LP-300 in never-smoker NSCLC patients. The trial expands into Asia due to higher prevalence of never-smoker NSCLC in East Asia. Preliminary U.S. results showed an 86% clinical benefit rate and 43% objective response rate.

The article discusses the importance of enabling JavaScript for optimal app performance.

Actuate Therapeutics will participate in Lantern Pharma’s “Webinar Wednesday” on Oct. 30, 2024, discussing the AI platform’s role in identifying and developing enrichment biomarkers for elraglusib, Actuate’s lead drug candidate. Elraglusib, a GSK-3β inhibitor, is in Phase 2 trials for metastatic pancreatic cancer and Phase 1/2 trials for Ewing Sarcoma.

Texas’s top hospitals recognized in 2025 America’s Best-in-State Hospitals ranking by Newsweek and Statista, with Houston Methodist Hospital leading. TCU and UT Arlington launch joint M.D.-Ph.D. program in biomedical engineering. UT Arlington’s North Texas Genome Center acquires $1 million next-generation genetic sequencer. Lantern Pharma’s LP-184 receives FDA Fast Track designation for treating glioblastoma.

FDA approves 420-mg trastuzumab-strf for HER2-overexpressing cancers, and zolbetuximab for CLDN18.2-positive gastric/GEJ adenocarcinoma. FDA delays decision on sotorasib plus panitumumab for KRAS G12C-mutated CRC to Jan 2025. LP-184 granted fast track designation for glioblastoma treatment.